The company has identified a vaccine as well as a passive immunotherapy with a selected monoclonal antibody which was highly active in animal models for Alzheimer’s disease. Both treatments significantly improved memory capacity in animal models.
Both therapies build on antibodies generated by AC Immune’s SupraAntigen Technology. They are conformation-specific and have induced the anticipated transition from the insoluble to the soluble form of the plaque-forming beta amyloid protein. This event directly correlated with the observed memory improvement.
“The highly significant functional improvement of memory function in Alzheimer’s disease animal models gives us a solid basis for the clinical development program in front of us,” said Andrea Pfeifer, CEO of AC Immune.